

# IntReALL

## International Study for Treatment of Childhood Relapsed ALL

### What's it all about?

No other form of cancer afflicts children so frequently as does acute lymphoblastic leukemia (ALL). In Europe, approx. 4/100.000 children and teens are diagnosed with this form of leukemia every year; approx. 0.7/100.000 relapse. **An ALL relapse is the most frequent cause of death among children suffering from cancer:** whereas the survival rate for new cases of ALL has risen substantially during the past thirty years the outlook for young patients who suffer a relapse has significantly worsened.

### What is IntReALL?

The Charité University Medical Department in Berlin is coordinating with the IntReALL EU project **an international study for the treatment of ALL relapse.** The goal of IntReALL is to develop an optimized internationally recognized standard therapy

for relapsed children with ALL so that more young patients can be permanently cured. Based on this best possible standard therapy the medical staff of the Charité and 22 international partners plan to test a series of new substances with regard to their efficacy in this patient group. **“We are convinced that this approach will lead to a significant reduction in the mortality rate of relapsed children,”** says study coordinator Dr. Arend von Stackelberg, head of Pediatric Oncology / Hematology at the Charité Campus Virchow Clinical Complex.

### Who is participating in this study?

Children and juveniles with acute lymphoblastic leukemia from all countries participating in the study may be recommended by their hospital for the study provided that they are medically suitable for participation. Whether they take part is decided by them and / or their parents. Age-appropriate explanatory material is available to support the decision-making process. Ethics commissions approve the study in all participating countries and are observing its course. On the whole it is projected that 250 to 300 patients from 250 hospitals will participate per year.

Families with children affected by this disease can consult their treating pediatric oncologists for further information.

### Why so many partners?

Even if ALL is the most frequent cancer in children it remains a rare disease nonetheless. The fact that ALL is so rare makes it more difficult to conduct comprehensive studies. A lack of a sufficient number of patients has meant that no study has been able to come about at the national level to test and approve promising drugs or therapy strategies. **That is why international cooperation is so important:** a total of 20 study groups from across Europe are coordinating the participation of approx. 300 patients a year. They include Germany's Medical School of Hanover, Switzerland's University of Zurich and Austria's St. Anna Children's Cancer Research Institute, in addition to the Karolinska Institute in Stockholm, the Tel Aviv Sourasky Medical Center and Oxford University. “For the first time a large number of participating hospitals and medical centers are providing the opportunity to conduct clinical trials in subgroups over a viable period of five years,” emphasizes Dr. von Stackelberg.

### And who is footing the bill?

The development of new drugs and therapies costs millions of euros. Rare diseases like ALL do not begin to receive the attention of the pharmaceuticals industry as do frequent diseases. **The EU Commission is funding the IntReALL project under the 7th Framework Programme with approx. Six million euros. The project is scheduled to run five years.**

## IntReALL's partners:

**Stichting Chatolic University**  
Nijmegen, The Netherlands

**Karolinska Institute**  
Stockholm, Sweden

**Baby Jesus Children's Hospital**  
Rome, Italy

**Population Genetics Technologies Ltd**  
Cambridge, UK

**ICCCPO (International Confederation of  
Childhood Cancer Parent Organizations)**  
Valencia, Spain

**The Francisco Gentil Portuguese Institute of  
Oncology**  
Lisbon, Portugal

**Wrocław Medical University**  
Wroclaw, Poland

**TP21 GmbH**  
Berlin, Germany

**Immunomedics, Inc.**  
Morris Plains NJ, USA

**University of Zurich**  
Zurich, Switzerland

**The Chancellor, Masters and Scholars of the  
University of Oxford**  
Oxford, UK

**Hospital District of Southwest Finland**  
Turku, Finland

**University Hospital in Motol**  
Prague, Czech Republic

**The University of Manchester**  
Manchester, UK

**The Foundation for Medical Research,  
Infrastructural Development and Health  
Services, next to the Tel Aviv Sourasky Medical  
Center**  
Tel Aviv, Israel

**XClinical GmbH**  
Munich, Germany

**Hospital Association of Brussels – University  
Hospital of the Children of Queen Fabiola**  
Brussels, Belgium

**St. Anna's Children's Cancer Research Institute**  
Vienna, Austria

**University Hospital Centre of Besançon**  
Besançon, France

**Medical School of Hanover**  
Hanover, Germany

**Capital Region of Denmark**  
Hillerød, Denmark

**Oslo University Hospital**  
Oslo, Norway

**European Organisation for Research and  
Treatment of Cancer (EORTC)**  
Belgium

## Project details:

**IntReALL** — International Study for the Treatment of Childhood **Relapsed ALL**. Initiated in 2010: standard therapy, systematic integration of new agents, and establishment of standardized diagnostic and research (HEALTH-F2-2011-278514).

**IntReALL** is funded by the 7th Framework Programme for Research and Technological Development of the European Commission.

Further information see [www.intreall-fp7.eu](http://www.intreall-fp7.eu)



Joining Together against  
the most Common Cancer  
Afflicting Children



International Study for Treatment of Childhood Relapsed ALL

International Study for Treatment of  
Childhood Relapsed ALL